This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ELTX Elicio Therapeutics (ELTX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock About Elicio Therapeutics Stock (NASDAQ:ELTX) 30 days 90 days 365 days Advanced Chart Get Elicio Therapeutics alerts:Sign Up Key Stats Today's Range$5.13▼$5.7550-Day Range N/A52-Week Range N/AVolume19,242 shsAverage Volume57,512 shsMarket Capitalization$59.35 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company OverviewAngion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.Read More… Elicio Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreELTX MarketRank™: Elicio Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 779th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingElicio Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageElicio Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Elicio Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Elicio Therapeutics are expected to grow in the coming year, from ($3.89) to ($3.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Elicio Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elicio Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElicio Therapeutics has a P/B Ratio of 4.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.95% of the float of Elicio Therapeutics has been sold short.Short Interest Ratio / Days to CoverElicio Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elicio Therapeutics has recently decreased by 3.13%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElicio Therapeutics does not currently pay a dividend.Dividend GrowthElicio Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.95% of the float of Elicio Therapeutics has been sold short.Short Interest Ratio / Days to CoverElicio Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elicio Therapeutics has recently decreased by 3.13%, indicating that investor sentiment is improving. News and Social MediaN/ANews SentimentN/A Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Elicio Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders28.65% of the stock of Elicio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 35.03% of the stock of Elicio Therapeutics is held by institutions.Read more about Elicio Therapeutics' insider trading history. Receive ELTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elicio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ELTX Stock News HeadlinesElicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New HiresApril 16, 2025 | globenewswire.comElicio Therapeutics reports FY24 EPS ($4.25) vs ($6.96) last yearApril 1, 2025 | markets.businessinsider.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.May 5, 2025 | Porter & Company (Ad)Elicio Therapeutics Inc.: Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate UpdatesMarch 31, 2025 | finanznachrichten.deElicio Therapeutics Reports 2024 Financial Results and Provides Corporate UpdatesMarch 31, 2025 | globenewswire.comELICIO THERAPEUTICS Earnings Preview: Recent $ELTX Insider Trading, Hedge Fund Activity, and MoreMarch 28, 2025 | nasdaq.comJonesTrading Sticks to Its Buy Rating for Elicio Therapeutics (ELTX)March 25, 2025 | markets.businessinsider.comElicio Therapeutics Hires CFO From Cidara TherapeuticsMarch 24, 2025 | marketwatch.comSee More Headlines ELTX Stock Analysis - Frequently Asked Questions How were Elicio Therapeutics' earnings last quarter? Elicio Therapeutics, Inc. (NASDAQ:ELTX) announced its earnings results on Monday, March, 31st. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.94) by $0.08. When did Elicio Therapeutics IPO? Elicio Therapeutics (ELTX) raised $40 million in an initial public offering (IPO) on the week of July 26th 2021. The company issued 3,100,000 shares at $12.00-$14.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager. Who are Elicio Therapeutics' major shareholders? Top institutional shareholders of Elicio Therapeutics include Moody Lynn & Lieberson LLC (0.09%). View institutional ownership trends. What other stocks do shareholders of Elicio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elicio Therapeutics investors own include Atreca (BCEL), Cytokinetics (CYTK), Datadog (DDOG), First Solar (FSLR), Intuitive Surgical (ISRG), Moderna (MRNA) and NVIDIA (NVDA). Company Calendar Last Earnings3/31/2025Today5/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ELTX CIK1555192 Webwww.angion.com Phone415-655-4899FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+81.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($6.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-555.45% Return on Assets-177.34% Debt Debt-to-Equity RatioN/A Current Ratio3.40 Quick Ratio3.40 Sales & Book Value Annual Sales$2.30 million Price / Sales25.80 Cash FlowN/A Price / Cash FlowN/A Book Value$1.35 per share Price / Book4.07Miscellaneous Outstanding Shares10,790,000Free Float7,699,000Market Cap$59.35 million OptionableNot Optionable Beta0.77 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ELTX) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.